- Citations, last 5 years
- 105
- Works, last 5 years
- 10
- h-index
- 26
- Scientists listed
- 1
- Grants since 2016
- 16
Grants received
2022–2024 · research · R41
Development of an improved intranasal vaccine against influenza
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2020–2027 · cooperative agreement · U44
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2020–2022 · cooperative agreement · U44
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2020–2027 · cooperative agreement · U44
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2019–2024 · cooperative agreement · U44
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2019–2021 · cooperative agreement · U44
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2019–2024 · cooperative agreement · U44
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2019–2020 · research · R43
Optimization of vaccine antigen for the development of improved influenza
Ian James Amanna · Najít Technologies (United States) · funded by Centers for Disease Control and Prevention
2019–2025 · cooperative agreement · U44
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2017–2022 · research · R44
Development of an H2O2-inactivated chikungunya virus vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Development of an H2O2-inactivated chikungunya virus vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Development of an H2O2-inactivated chikungunya virus vaccine
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2016–2018 · research · R41
Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2008–2021 · research · R44
Development of a Yellow Fever Vaccine for a Vulnerable Population
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2008–2021 · research · R44
Development of a Yellow Fever Vaccine for a Vulnerable Population
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
2008–2021 · research · R44
Development of a Yellow Fever Vaccine for a Vulnerable Population
Ian James Amanna · Najít Technologies (United States) · funded by National Institutes of Health
